Korean Stem Cell Med for Sale

South Korea approves the first stem-cell medication for clinical use.

By | July 8, 2011

LEONARDINI / STOCK.XCHNG

After six years of clinical trials, the South Korean Food and Drug Administration approved a stem-cell-based treatment for commercial sale last week—making South Korea the first country where a stem cell medication has been green-lighted for clinical use. Developed by FCB-Pharmicell, a Korean biotech that specializes in stem cell drugs, Hearticellgram-AMI consists of an injection of somatic stem cells cultured from the bone marrow into the coronary arteries of patients who have suffered from acute myocardial infarction. According to the company, just one injection is enough to promote a 6 percent improvement in heart function after 6 months. However, there has been concern over a lack of independent validation of the treatment, Reuters reports, as FCB-Pharmicell’s new product is yet to be vetted by a peer review publication.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Gut Microbes Linked to Neurodegenerative Disease
  2. Top 10 Innovations 2016
    Features Top 10 Innovations 2016

    This year’s list of winners celebrates both large leaps and small (but important) steps in life science technology.

  3. Opinion: WHO’s Silence on Cannabis
  4. Image of the Day: Parting Ways
    Image of the Day Image of the Day: Parting Ways

    The Allen Institute for Cell Science releases the first public collection of human induced pluripotent stem cells that have been fluorescently tagged using CRISPR.

Rockland